Thrombocytosis as a biomarker in type ii, non-endometrioid endometrial cancer

Parker Bussies, Ayi Eta, Andre Pinto, Sophia George, Matthew Schlumbrecht

Research output: Contribution to journalArticlepeer-review


Thrombocytosis (platelets ≥ 400K) is a common hematologic finding in gynecologic malignancies and associated with worse outcomes. Limited data exist on the prognostic capability of thrombocytosis in women with high-grade endometrial cancer (EC). Our objective was to describe the associations between elevated platelets at diagnosis, clinicopathologic features, and survival outcomes among women with high-grade, non-endometrioid EC. A review of the institutional cancer registry was performed to identify these women treated between 2005 and 2017. Sociodemographic, clinical, and outcomes data were collected. Analyses were performed using chi-square tests, Cox proportional hazards models, and the Kaplan–Meier method. A total of 271 women were included in the analysis. A total of 19.3% of women had thrombocytosis at diagnosis. Thrombocytosis was associated with reduced median overall survival (OS) compared with those not displaying thrombocytosis (29.4 months vs. 60 months, p < 0.01). This finding was most pronounced in uterine serous carcinoma (16.4 months with thrombocytosis vs. 34.4 months without, p < 0.01). While non-White women had shorter median OS for the whole cohort in the setting of thrombocytosis (29.4 months vs. 39.6 months, p < 0.01), among those with uterine serous carcinoma (USC), this finding was reversed, with decreased median OS in White women (22.1 vs. 16.4 months, p = 0.01). Thrombocytosis is concluded to have negative associations with OS and patient race.

Original languageEnglish (US)
Article number2379
Pages (from-to)1-12
Number of pages12
Issue number9
StatePublished - Sep 2020


  • Endometrial cancer
  • Platelets
  • Race
  • Serous
  • Survival
  • Thrombocytosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Thrombocytosis as a biomarker in type ii, non-endometrioid endometrial cancer'. Together they form a unique fingerprint.

Cite this